Hantz Financial Services’s Ultragenyx Pharmaceutical RARE Stock Holding History

Hantz Financial Services’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2K	Hold	51	–	–	﹤0.01%	2329
2026 Q1	$1K	Sell	51 -13	-20%	-$293	﹤0.01%	2391
2025 Q4	$1K	Hold	64	–	–	﹤0.01%	2354
2025 Q3	$2K	Sell	64 -3,174	-98%	-$95.2K	﹤0.01%	2196
2025 Q2	$118K	Sell	3,238 -215	-6%	-$7.75K	﹤0.01%	724
2025 Q1	$125K	Buy	3,453 +86	+3%	+$3.58K	﹤0.01%	601
2024 Q4	$142K	Sell	3,367 -132	-4%	-$6.55K	﹤0.01%	582
2024 Q3	$194K	Buy	+3,499	New	+$178K	﹤0.01%	567

Other funds holding RARE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Hantz Financial Services's RARE Position: Q2 2026 in Review

Hantz Financial Services held its Ultragenyx Pharmaceutical (RARE) position steady in Q2 2026 at 51 shares worth $2K. The position accounts for ﹤0.01% of the portfolio, ranked #2329.

Hantz Financial Services first reported a position in RARE in Q3 2024 and has held it in 8 quarters since. The position peaked at $194K in Q3 2024. 311 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

Hantz Financial Services held 51 shares of Ultragenyx Pharmaceutical worth $2K as of Q2 2026.
Hantz Financial Services left its Ultragenyx Pharmaceutical share count unchanged in Q2 2026.
Ultragenyx Pharmaceutical made up ﹤0.01% of Hantz Financial Services's portfolio in Q2 2026, its #2329 holding.
Hantz Financial Services first reported a position in Ultragenyx Pharmaceutical in Q3 2024 and has held it in 8 quarters since.
Hantz Financial Services's Ultragenyx Pharmaceutical position peaked at $194K in Q3 2024.
311 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on Hantz Financial Services's 13F filing for Q2 2026, filed 13 Aug 2026.